Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Virtual Congress 2020

What to do with patients who attend appointments with a next generation sequencing (NGS) platform dataset

Q&A and live discussion

Date

18 Oct 2020

Session

What to do with patients who attend appointments with a next generation sequencing (NGS) platform dataset

Topics

Tumour Site

Head and Neck Cancers

Presenters

Kevin Harrington

Authors

K.J. Harrington

Author affiliations

  • Dept. Of Radiotherapy And Imaging, ICR - Institute of Cancer Research - Chester Beatty Laboratories, SW3 6JB - London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction and HPV-

Presenter: Kevin Harrington

Session: What to do with patients who attend appointments with a next generation sequencing (NGS) platform dataset

Resources:

Slides

Webcast

HPV+

Presenter: Amanda Psyrri

Session: What to do with patients who attend appointments with a next generation sequencing (NGS) platform dataset

Resources:

Slides

Webcast

Nasal, para-nasal and skull base tumours

Presenter: Lisa Licitra

Session: What to do with patients who attend appointments with a next generation sequencing (NGS) platform dataset

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.